 | Up a level |
Journal Article
Cooper, Jason P., Storer, Barry E., Granot, Noa, Gyurkocza, Boglarka, Sorror, Mohamed L., Chauncey, Thomas R., Shizuru, Judith, Franke, Georg-Nikolaus, Maris, Michael B., Boyer, Michael, Bruno, Benedetto, Sahebi, Firoozeh, Langston, Amelia A., Hari, Parameswaran, Agura, Edward D., Petersen, Soren Lykke, Maziarz, Richard T., Bethge, Wolfgang, Asch, Julie, Gutman, Jonathan A., Olesen, Gitte, Yeager, Andrew M., Hubel, Kai, Hogan, William J., Maloney, David G., Mielcarek, Marco, Martin, Paul J., Flowers, Mary E. D., Georges, George E., Woolfrey, Ann E., Deeg, H. Joachim, Scott, Bart L., McDonald, George B., Storb, Rainer and Sandmaier, Brenda M. (2021). Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies improved outcomes over two decades. Haematologica, 106 (6). S. 1599 - 1608. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Garcia-Manero, Guillermo, Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R., Sekeres, Mikkael A., Roboz, Gail J., Gaidano, Gianluca, Scott, Bart L., Greenberg, Peter, Platzbecker, Uwe, Steensma, David P., Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A., Atallah, Ehab, Collins, Robert, Jr., Kantarjian, Hagop, Jabbour, Elias, Wilhelm, Francois E., Azarnia, Nozar and Silverman, Lewis R. (2016). Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol., 17 (4). S. 496 - 509. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
Garcia-Manero, Guillermo, Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R., Sekeres, Mikkael A., Roboz, Gail J., Gaidano, Gianluca, Scott, Bart L., Greenberg, Peter L., Platzbecker, Uwe, Steensma, David P., Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A., Collins, Robert, Atallah, Ehab, Wilhelm, Francois, Wilhelm, Isabelle E., Azarnia, Nozar, Maniar, Manoj and Silverman, Lewis R. (2014). Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Silverman, Lewis R., Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R., Sekeres, Mikkael A., Roboz, Gail J., Gaidano, Gianluca, Scott, Bart L., Greenberg, Peter L., Platzbecker, Uwe, Steensma, David P., Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A., Collins, Robert, Atallah, Ehab, Navada, Shyamala C., Wilhelm, Francois, Azarnia, Nozar and Garcia-Manero, Guillermo (2014). Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020